Assaf Chalid, Sterry Wolfram
Skin Cancer Center Charité, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Fabeckstr 60-62, 14195 Berlin, Germany.
Curr Opin Mol Ther. 2007 Apr;9(2):197-203.
Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. Zanolimumab is currently undergoing phase III clinical trials for CTCL and phase II clinical trials for NCTCL.
默克雪兰诺公司（Merck Serono SA）获得了丹麦Genmab A/S公司和美国Medarex公司的授权，正在开发扎诺木单抗（zanolimumab），这是一种靶向CD4的人源单克隆抗体，用于潜在治疗皮肤型（CTCL）和非皮肤型（NCTCL）T细胞淋巴瘤。扎诺木单抗目前正在进行CTCL的III期临床试验和NCTCL的II期临床试验。
